Introduction {#s1}
============

The regulation of energy balance (food consumption and energy expenditure) is important for health and survival. Sustained negative energy balance caused by cachexia and anorexia is associated with serious injury to multiple organ systems ([@bib2]; [@bib34]). Similarly, sustained positive energy balance caused by hyperphagia results in obesity associated with severe metabolic disorders (e.g. type 2 diabetes, cardiovascular disease, hepatitis, neurodegeneration and cancer) that represent leading causes of morbidity and mortality ([@bib21]). The homeostatic maintenance of energy balance is therefore critically important.

It is established that the arcuate nucleus (ARC) in the hypothalamus plays a key role in the regulation of energy balance ([@bib13]). AgRP neurons in the ARC mediate orexigenic signals, including neuropeptide Y (NPY), agouti-related peptide (AgRP), and γ-aminobutyric acid (GABA) that project to POMC neurons in the ARC and to secondary response neurons in many brain regions, including the lateral hypothalamus (LH) and the paraventricular nucleus (PVN) of the hypothalamus. In contrast, POMC neurons mediate anorexigenic signals, including cocaine and amphetamine regulated transcript (CART) and pro-opiomelanocortin (POMC)-derived α-melanocyte stimulating hormone (α-MSH). POMC neurons project to many brain areas, including the PVN and LH in the hypothalamus where α-MSH acts as an agonist of the melanocortin receptors MC3R and MC4R on secondary response neurons to inhibit feeding and increase energy expenditure. Importantly, this action of α-MSH is antagonized by AgRP. Moreover, POMC neurons receive inhibitory GABAergic input from AgRP neurons. Consequently, AgRP and POMC neurons act together to balance food consumption, energy expenditure and nutrient homeostasis ([@bib13]).

AgRP and POMC neurons integrate signals from nutrients (e.g. glucose and fatty acids) and peripheral hormones (e.g. leptin, insulin, ghrelin, and cytokines) to mediate opposite actions regulating downstream neuroendocrine circuits linking internal and environmental stimuli with the coordinated control of homeostatic satiety ([@bib8]; [@bib53]). Thus, leptin activates POMC neurons ([@bib14]) and inhibits AgRP neurons ([@bib48]) leading to reduced food consumption and increased energy expenditure. These processes can be regulated by intracellular signaling networks, including the Janus kinase 2-signal transducer and activator of transcription 3 (JAK2-STAT3) axis ([@bib4]), Rho-associated coiled coil containing protein kinase 1 (ROCK1) ([@bib26]), mechanistic target of rapamycin (mTOR) ([@bib35]; [@bib30]), adenosine monophosphate-activated protein kinase (AMPK) ([@bib10]; [@bib15]), and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) ([@bib37]), that contribute to the fine-tuning of energy balance.

The anorexigenic hormone leptin plays a key role in the regulation of food consumption. Leptin can act directly on AgRP and POMC neurons, but leptin can also act on other neurons in several brain sub-regions, including mid-brain and brainstem nuclei ([@bib47]; [@bib41]). Control of leptin signaling in these neurons is important for maintaining energy balance. For example, obesity causes an increase in the blood concentration of leptin, most likely because of increased adipose tissue mass. The increased leptin concentration can lead to tachyphylaxis and suppression of the anorexigenic actions of leptin ([@bib22]). This mechanism enables homeostatic regulation of feeding behavior in response to metabolic stress. Whether this mechanism represents "leptin resistance" is unclear ([@bib36]) because some biochemical aspects of leptin signaling are maintained in the obese state ([@bib39]). A requirement for leptin signaling may reflect the role of the leptin-stimulated JAK2-STAT3 pathway to increase expression of the negative regulator SOCS3 ([@bib1]). Negative regulation of leptin signaling may also involve the tyrosine phosphatases PTPN1 and PTPN2 ([@bib7]; [@bib33]), reactive oxygen species ([@bib19]), the endoplasmic reticulum unfolded protein response ([@bib58]; [@bib40]), autophagy ([@bib27]), and low-grade inflammation ([@bib17]).

The purpose of the study reported here was to test whether the cJun NH~2~-terminal kinase (JNK) signaling pathway regulates feeding behavior. Previous studies have established that the ubiquitously expressed JNK1 and JNK2 isoforms play an important role in the metabolic stress response of peripheral tissues ([@bib45]). However, loss-of-function studies have not identified a role for JNK in the control of food consumption. Here we demonstrate that the neuronal isoform JNK3 (encoded by the *Mapk10* gene) plays a key role in the maintenance of energy balance during consumption of a high fat diet (HFD) by promoting leptin signaling. *Mapk10* gene ablation studies identify AgRP neurons as a site of JNK3 function. JNK3 is therefore a key mediator of homeostatic regulation of energy balance in response to metabolic stress.

Results {#s2}
=======

Feeding a high fat diet causes JNK3 activation {#s2-1}
----------------------------------------------

Leptin is an anorexigenic hormone. Indeed, treatment of chow-fed mice with leptin suppressed feeding behavior and caused decreased body mass ([Figure 1A](#fig1){ref-type="fig"}). In contrast, HFD-fed mice failed to respond to leptin ([Figure 1A](#fig1){ref-type="fig"}). The mechanism that accounts for this observation is unclear, but may involve both decreased leptin signaling and reduced signaling by down-stream mediators (e.g. MC4R). Tachyphylaxis may be a contributing factor and mutational analysis of leptin signaling components implicates functions of the leptin receptor, tyrosine phosphatases, reactive oxygen species, and SOCS3 ([@bib36]).10.7554/eLife.10031.003Figure 1.JNK3 deficiency causes hyperphagia and obesity.(**A**) WT mice were fed (4 wk) a chow diet (CD) or a high-fat diet (HFD). The body mass change at 24 hr post-injection (i.p. with solvent (PBS) or 2.5 mg/kg leptin) was measured (mean ± SEM; n=8; \*\*\*p\<0.001). (**B**) WT and *Mapk10^-/-^* mice fed (12 wk) a CD or a HFD were starved overnight. Phospho-JNK3, JNK3, and GAPDH in the hypothalamus were measured by immunoblot analysis. (**C**,**D**) The body mass gain of CD-fed and HFD-fed (12 wk) mice was measured (mean ± SEM; n=10\~12) (**C**). Fat and lean mass were measured by ^1^H-MRS analysis (mean ± SEM; n=10\~12). (**D**) Statistically significant differences between WT and *Mapk10^-/-^*mice are indicated (\*\*\*p\<0.001). (**E**) Paraffin embedded sections of epididymal white adipose tissue (WAT), interscapular brown adipose tissue (BAT), and liver were prepared from HFD-fed (12 wk) WT and *Mapk10^-/-^* mice. The sections were stained with hematoxylin & eosin. Scale bar, 100 µm. (**F**) Food consumption by WT and *Mapk10^-/-^* mice fed a CD or a HFD (3 wk) was measured (mean ± SEM; n=6; \*\*p\<0.01; \*\*\*p\<0.001). (**G**) WT and *Mapk10^-/-^* mice fed a CD or a HFD (4 wk) were fasted overnight and the blood concentration of leptin and insulin was measured (mean ± SE; n=10\~12; \*p\<0.05). (**H**,**I**) Glucose tolerance tests (**H**) and insulin tolerance tests (**I**) were performed on WT and *Mapk10^-/-^* mice fed a CD or a HFD (12 wk) by measurement of blood glucose concentration (mean ± SEM; n=10\~12; \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001).**DOI:** [http://dx.doi.org/10.7554/eLife.10031.003](10.7554/eLife.10031.003)10.7554/eLife.10031.004Figure 1---figure supplement 1.JNK3 deficiency causes obesity without changes in energy expenditure.(**A**) Organ mass of CD-fed and HFD-fed (12 wk) WT and *Mapk10^-/-^* mice was measured (mean ± SEM; n=10\~12; \*p\<0.05; \*\*\*p\<0.001). (**B**) CD-fed and HFD-fed (4 wk) WT and *Mapk10^-/-^* mice were examined using metabolic cages to measure V~O2~, V~CO2~, and energy expenditure (mean ± SEM; n=8; \*\*\*p\<0.001). (**C**) Blood lipids and lipoproteins in overnight starved CD-fed and HFD-fed (12 wk) WT and *Mapk10^-/-^* mice were measured (mean ± SEM; n=10\~12; \*\*p\<0.01; \*\*\*p\<0.001).**DOI:** [http://dx.doi.org/10.7554/eLife.10031.004](10.7554/eLife.10031.004)10.7554/eLife.10031.005Figure 1---figure supplement 2.Time course of the development of hyperphagia in HFD-fed JNK3-deficient mice.(**A**) Metabolic cage analysis of WT and *Mapk10^-/-^* mice fed a HFD. The amount of food consumed 7pm -- 7am each day was measured (mean ± SEM; n=6; \*p\<0.05; \*\*p\<0.01). (**B**) Fat and lean body mass of WT and *Mapk10^-/-^* mice fed a HFD (3 days) was measured by ^1^H-MRS analysis (mean ± SEM; n=6). No statistically significant differences were detected (p\>0.05).**DOI:** [http://dx.doi.org/10.7554/eLife.10031.005](10.7554/eLife.10031.005)10.7554/eLife.10031.006Figure 1---figure supplement 3.Increased food consumption is required for obesity caused by JNK3 deficiency in HFD-fed mice.WT and *Mapk10^-/-^* mice were fed a HFD *ad libitum*. A second group of *Mapk10^-/-^* mice were pair-fed with the WT mice. The change in body mass was measured (mean ± SEM; n= 6; \*\*p\<0.01).**DOI:** [http://dx.doi.org/10.7554/eLife.10031.006](10.7554/eLife.10031.006)

We considered the possibility that a stress-activated MAP kinase pathway may contribute to the regulation of leptin signaling in HFD-fed mice. It is established that feeding a HFD causes activation of the ubiquitously expressed isoforms JNK1 and JNK2 in peripheral tissues, including liver, muscle, and adipose tissue ([@bib45]). However, the regulation of JNK caused by feeding a HFD in the central nervous system is unclear because these ubiquitously expressed JNK isoforms in neurons are constitutively activated and are primarily localized to axons and dendrites ([@bib11]; [@bib38]). In contrast, the neuron-specific isoform JNK3 exhibits low basal activity and can be activated in the nucleus when neurons are exposed to environmental stress ([@bib57]). We therefore tested whether feeding a HFD caused activation of JNK3. This analysis demonstrated that feeding a HFD caused JNK3 phosphorylation and activation in the hypothalamus ([Figure 1B](#fig1){ref-type="fig"}). JNK3 in the central nervous system is therefore responsive to diet-induced metabolic stress. This JNK3 pathway represents a possible mediator of altered leptin signaling in HFD-fed mice.

JNK3 deficiency promotes obesity and insulin resistance {#s2-2}
-------------------------------------------------------

To examine the role of the JNK3 pathway, we investigated the effect of feeding a chow diet (CD) or a HFD to wild-type (WT) mice or *Mapk10^-/-^* (JNK3-deficient) mice. We found that *Mapk10^-/-^* mice gained similar body mass when fed a CD, but these mice gained significantly greater mass when fed a HFD compared with WT mice ([Figure 1C](#fig1){ref-type="fig"}). ^1^H-MRS analysis demonstrated that the greater HFD-induced body mass was caused by increased fat and lean mass ([Figure 1D](#fig1){ref-type="fig"}). Indeed, HFD-fed *Mapk10^-/-^* mice exhibited increased liver, skeletal muscle, heart, and adipose tissue mass compared with HFD-fed WT mice ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Microscopic examination of tissue sections demonstrated increased hypertrophy of white and brown adipocytes and increased hepatic steatosis in HFD-fed *Mapk10^-/-^* mice compared with HFD-fed WT mice ([Figure 1E](#fig1){ref-type="fig"}).

We performed metabolic cage analysis to examine the mechanism of obesity promoted by JNK3 deficiency. These studies demonstrated that *Mapk10* gene ablation selectively increased consumption of a HFD, but not a CD ([Figure 1F](#fig1){ref-type="fig"}). Time course analysis demonstrated that the HFD-selective hyperphagia was observed within 2 days of consuming the HFD ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}) and was detected prior to the development of obesity ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). No significant changes in V~O2~, V~CO2~, or energy expenditure were detected in the HFD-fed mice ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). These data suggest that hyperphagia contributes to the increased obesity of HFD-fed *Mapk10^-/-^* mice compared with HFD-fed WT mice.

We used a pair-feeding protocol to test whether the increased obesity of *Mapk10^-/-^* mice compared with WT mice was caused by greater food consumption. We found that WT and *Mapk10^-/-^* mice gained similar body mass when fed the same amount of food ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). These data demonstrate that hyperphagia accounts for the increased HFD-induced obesity of *Mapk10^-/-^* mice compared with WT mice.

Consequences of the increased HFD feeding behavior of *Mapk10^-/-^* mice include increased hyperinsulinemia and hyperleptinemia ([Figure 1G](#fig1){ref-type="fig"}), increased blood lipid concentrations ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}), decreased glucose tolerance ([Figure 1H](#fig1){ref-type="fig"}), and increased insulin resistance ([Figure 1I](#fig1){ref-type="fig"}) when fed a HFD, but not a CD. These data indicate that *Mapk10^-/-^* mice may exhibit increased HFD-induced insulin resistance. To test this hypothesis, we performed a hyperinsulinemic-euglycemic clamp study. No significant differences between CD-fed WT and *Mapk10^-/-^* mice were detected ([Figure 2A--F](#fig2){ref-type="fig"}). In contrast, HFD-fed *Mapk10^-/-^* mice showed significantly reduced glucose infusion rate (a measure of whole body insulin sensitivity), reduced glucose turnover, reduced whole body glycolysis, increased hepatic glucose production, and decreased hepatic insulin action compared with HFD-fed WT mice ([Figure 2A--F](#fig2){ref-type="fig"}). These data demonstrate that *Mapk10^-/-^* mice exhibit a profound defect in glycemic regulation compared with WT mice when fed a HFD, but not a CD.10.7554/eLife.10031.007Figure 2.JNK3 deficiency promotes and adipose tissue inflammation and insulin resistance.(**A-F**) Hyperinsulinemic-euglycemic clamps were performed on CD-fed or HFD-fed (3 wk) WT and *Mapk10^-/-^* mice. Clamp hepatic glucose production (**A**), hepatic insulin action (**B**), glucose turnover (**C**), glucose infusion rate (**D**), whole body glycolysis (**E**), and glycogen plus lipid synthesis (**F**) were measured (mean ± SE; n=8; \*p\<0.05; \*\*\*p\<0.001). (**G-J**) Sections of epididymal WAT from HFD-fed (12 wk) WT and *Mapk10^-/-^* mice were stained with hematoxylin & eosin or with an antibody to the macrophage protein F4/80 (**G**). Macrophage infiltration was examined by measurement of the expression of *Cd68* and *Emr1 (F4/80)* mRNA (**H**) and also mRNA expressed by genes associated with M1-like (**I**) and M2-like (**J**) polarization by Taqman^©^ assays (mean ± SEM; n=10\~12; \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001).**DOI:** [http://dx.doi.org/10.7554/eLife.10031.007](10.7554/eLife.10031.007)

JNK3 deficiency promotes adipose tissue inflammation {#s2-3}
----------------------------------------------------

The increased adipose tissue mass of HFD-fed *Mapk10^-/-^* mice compared with HFD-fed control mice was associated with increased adipose tissue infiltration by F4/80^+^ macrophages ([Figure 2G](#fig2){ref-type="fig"}). Indeed, gene expression analysis identified markedly increased expression of macrophage marker genes (*Emr1* (F4/80) & *Cd68*), increased expression of genes associated with M1-like macrophage polarization (*Ccl2, Il1b, Il6* & *Tnf*), and decreased expression of genes associated with M2-like macrophage polarization (*Arg1, Mgl2, Mrc1* & *Mrc2*) in the adipose tissue of HFD-fed *Mapk10^-/-^* mice compared with HFD-fed control mice ([Figure 2H--J](#fig2){ref-type="fig"}). These data indicate that JNK3 deficiency promotes increased adipose tissue inflammation in HFD-fed mice. It is likely that this increase in inflammation contributes to the glucose intolerant and insulin resistant phenotype of HFD-fed *Mapk10^-/-^* mice compared with HFD-fed WT mice ([@bib9]).

JNK3 deficiency suppresses leptin signaling {#s2-4}
-------------------------------------------

Low concentrations of leptin were detected in the blood when WT and *Mapk10^-/-^* mice were fed a CD ([Figure 1G](#fig1){ref-type="fig"}). The blood leptin concentration was increased when these mice were fed a HFD and was significantly greater in HFD-fed *Mapk10^-/-^* mice compared with HFD-fed WT mice ([Figure 1G](#fig1){ref-type="fig"}). These changes in the amount of leptin circulating in the blood correlate, as expected, with differences in obesity ([@bib23]). However, the hyperleptinemia and hyperphagia of HFD-fed *Mapk10^-/-^*mice is not consistent with the established anorexigenic function of leptin. This analysis suggested that leptin signaling may be suppressed in HFD-fed *Mapk10^-/-^* mice. To test this hypothesis, we examined the effect of treating mice with leptin. We found that intracerebroventricular administration of leptin decreased the body mass of WT mice, but not *Mapk10^-/-^* mice ([Figure 3A](#fig3){ref-type="fig"}). Measurement of hypothalamic gene expression demonstrated that leptin decreased *Agrp* and *Npy* expression in WT mice, but not *Mapk10^-/-^* mice ([Figure 3B](#fig3){ref-type="fig"}). In contrast, leptin caused increased *Pomc* and *Socs3* gene expression in both WT and *Mapk10^-/-^* mice ([Figure 3B](#fig3){ref-type="fig"}). These data indicate that *Mapk10^-/-^* mice exhibit a selective deficiency in leptin regulation of *Agrp* and *Npy* expression. To confirm this conclusion, we compared hypothalamic gene expression in CD-fed and HFD-fed mice. This analysis demonstrated increased *Agrp* and *Npy* expression in HFD-fed *Mapk10^-/-^* mice compared with HFD-fed WT mice ([Figure 3C](#fig3){ref-type="fig"}). In contrast, no significant difference in *Pomc* and *Socs3* gene expression between HFD-fed WT and *Mapk10^-/-^* mice was detected ([Figure 3C](#fig3){ref-type="fig"}). These observations indicate that JNK3 deficiency caused a selective defect in leptin signaling.10.7554/eLife.10031.008Figure 3.JNK3 deficiency causes a selective defect in AgRP neurons.(**A**) HFD-fed (4 wk) WT and *Mapk10^-/-^* mice were treated by intracerebroventricular administration of 5 µg leptin or solvent (Control). The change in body mass at 24 hr post-treatment was measured (mean ± SEM; n=10\~12; \*\*\*p\<0.001). (**B**) WT and *Mapk10^-/-^* mice were treated without or with leptin (2h) prior to measurement of hypothalamic gene expression by Taqman^©^ assays (mean ± SEM; n=10\~12; \*p\<0.05). (**C**) Hypothalamic gene expression in CD-fed and HFD-fed (12 wk) WT and *Mapk10^-/-^* mice was measured by Taqman^©^ assay (mean ± SEM; n=10\~12; \*p\<0.05).**DOI:** [http://dx.doi.org/10.7554/eLife.10031.008](10.7554/eLife.10031.008)

LEPRb^+^ neurons mediate the effects of JNK3 on feeding behavior {#s2-5}
----------------------------------------------------------------

To examine the mechanism of JNK3 function, we established floxed *Mapk10* mice to investigate the neuron-specific effects of JNK3 on feeding behavior ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). We tested whether JNK3 in neurons that express the leptin receptor LEPRb regulates feeding behavior by investigating the effect of *Mapk10* gene ablation specifically in LEPRb^+^ neurons. This analysis demonstrated that control *Leprb-cre* (LepR^WT^) mice and *Leprb-cre Mapk10^Loxp/LoxP^* (LepR^∆J3^) mice gained similar body mass when fed a CD. However, HFD-fed LepR^∆J3^ mice gained significant more body mass than LepR^WT^ mice ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}). ^1^H-MRS analysis showed that the difference in body mass was caused by increased fat mass ([Figure 4B](#fig4){ref-type="fig"}). Metabolic cage analysis demonstrated that *Mapk10* gene ablation in LEPRb^+^ neurons caused no change in CD food consumption, but caused increased HFD food consumption ([Figure 4C](#fig4){ref-type="fig"}). This increase in HFD consumption was not associated with changes in V~O2~, V~CO2~, or energy expenditure ([Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}). JNK3 in LEPRb^+^ neurons of HFD-fed mice therefore regulates feeding behavior, but not other aspects of energy balance.10.7554/eLife.10031.009Figure 4.JNK3 deficiency in leptin-responsive neurons causes HFD-induced hyperphagia and obesity.(**A**) The total body mass gain of CD-fed and HFD-fed mice was examined (mean ± SEM; n = 10\~25; \*p\<0.05; \*\*p\<0.01). JNK3 deficiency in LEPRb^+^ neurons was studied by comparing *Leprb-cre* control mice (LepRb^WT^ mice) and *Leprb-cre Mapk10^LoxP/LoxP^*mice (LepR^∆J3^ mice). (**B**) The fat and lean mass of CD-fed and HFD-fed (16 wk) mice was measured by ^1^H-MRS analysis (mean ± SEM; n = 8\~10; \*\*p\<0.001). (**C**) Food consumption by CD-fed and HFD-fed (4 wk) LepR^WT^ and LepR^∆J3^ mice was examined (mean ± SEM; n = 8; \*p\<0.05). (**D**,**E**) Glucose tolerance (**D**) and insulin tolerance (**E**) tests were performed using CD-fed and HFD-fed (12 wk) LepR^WT^ and LepR^∆J3^ mice (mean ± SEM; n = 8\~12; \*p\<0.05; \*\*p\<0.01). (**F-H**) CD-fed and HFD-fed (12 wks) LepR^WT^ and LepR^∆J3^ mice were fasted overnight and the blood concentration of glucose (**F**), insulin (**G**), and leptin (**H**) was measured (mean ± SEM; n = 8\~20; \*p\<0.05\*\*p\<0.01). (**I**) Sections of epididymal WAT, interscapular BAT, and liver from CD-fed and HFD-fed (12 wk) LepR^WT^ and LepR^∆J3^ mice were stained with hematoxylin & eosin. Bar, 100 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.10031.009](10.7554/eLife.10031.009)10.7554/eLife.10031.010Figure 4---figure supplement 1.Establishment of *Mapk10^LoxP/LoxP^*mice.(**A**) The strategy employed to target the *Mapk10* locus (exons 6--9) by homologous recombination is illustrated. Restriction sites and PCR amplimers are indicated. Abbreviations: NEO, neomycin resistance cassette; and DT, diptheria toxin cassette. (**B**) The integrity of 5' and 3' *LoxP* sites of the *Mapk10^LoxP^* allele were verified by PCR analysis of genomic DNA using amplimers 1F & 2R (5' site) and 3F & 5R (3' site). (**C**) Comparison of hypothalamic expression of selected genes in WT and *Mapk10^LoxP/LoxP^*mice by Taqman^©^ assays. No significant differences (p\>0.05) between WT and *Mapk10^LoxP/LoxP^*mice were detected (mean ± SEM; n=3). (**D**) PCR genotype analysis of DNA isolated from different tissues of WT mice, *Mapk10^LoxP/LoxP^*mice, *Agrp-cre Mapk10^LoxP/LoxP^*mice (Agrp^∆J3^), *Pomc-cre Mapk10^LoxP/LoxP^*mice (Pomc^∆J3^), and *LepRb-cre Mapk10^LoxP/LoxP^*mice (LepR^∆J3^) using amplimers 1F & 2R (upper panel) and 1F & 4R (lower panel).**DOI:** [http://dx.doi.org/10.7554/eLife.10031.010](10.7554/eLife.10031.010)10.7554/eLife.10031.011Figure 4---figure supplement 2.JNK3 deficiency in leptin-responsive neurons causes obesity.(**A**) Organ mass of CD-fed and HFD-fed (16 wk) *LepRb-cre* (Lepr^WT^) and *LepRb-cre Mapk10^Loxp/LoxP^*(Lepr^∆J3^) mice was measured (mean ± SEM; n=10\~12; \*\*p\<0.01; \*\*\*p\<0.001). (**B**) CD-fed and HFD-fed (4 wk) Lepr^WT^ and Lepr^∆J3^ mice were examined using metabolic cages to measure V~O2~, V~CO2~, and energy expenditure (mean ± SEM; n=8; \*p\<0.05).**DOI:** [http://dx.doi.org/10.7554/eLife.10031.011](10.7554/eLife.10031.011)

The increased feeding behavior of HFD-fed (but not CD-fed) LepR^∆J3^ mice was associated with decreased glucose tolerance ([Figure 4D](#fig4){ref-type="fig"}), increased insulin resistance ([Figure 4E](#fig4){ref-type="fig"}), increased blood glucose concentration ([Figure 4F](#fig4){ref-type="fig"}), increased hyperinsulinemia ([Figure 4G](#fig4){ref-type="fig"}), and increased hyperleptinemia ([Figure 4H](#fig4){ref-type="fig"}). White and brown adipose tissue (WAT & BAT) in HFD-fed LepR^∆J3^ mice exhibited increased adipocyte hypertrophy compared with HFD-fed LepR^WT^ mice ([Figure 4I](#fig4){ref-type="fig"}). Moreover, JNK3 deficiency in LepRb^+^ neurons caused increased HFD-induced hepatic steatosis ([Figure 4I](#fig4){ref-type="fig"}).

JNK3 in AgRP neurons suppresses HFD feeding behavior {#s2-6}
----------------------------------------------------

To identify a LepRb^+^ neuronal sub-population relevant to JNK3-regulated HFD feeding behavior, we examined *Mapk10* gene ablation in selected neurons within the hypothalamus. Gene expression analysis demonstrated that JNK3 was required for HFD-induced regulation of *Agrp* and *Npy*, but not *Pomc* ([Figure 3](#fig3){ref-type="fig"}). This analysis indicated that AgRP neurons rather than POMC neurons may play an important role in JNK3-regulated feeding behavior in HFD-fed mice. To test this hypothesis, we examined the phenotype of *Agrp-cre Mapk10^Loxp/LoxP^* (Agrp^∆J3^) mice and *Pomc-cre Mapk10^Loxp/LoxP^* (Pomc^∆J3^) mice. We found that JNK3 deficiency in POMC neurons of HFD-fed mice caused no significant changes in feeding behavior, glucose intolerance, blood glucose concentration, hypertrophy of white and brown adipocytes, and hepatic steatosis compared with control *Pomc-cre* (Pomc^WT^) mice ([Figure 5A,C,E](#fig5){ref-type="fig"}). In contrast, JNK3 deficiency in AgRP neurons in HFD-fed mice caused increased feeding, increased glucose intolerance, increased blood glucose concentration, increased hypertrophy of white and brown adipocytes, and increased hepatic steatosis compared with control *Agrp-cre* (Agrp^WT^) mice ([Figure 5B,D,F](#fig5){ref-type="fig"}). Metabolic cage analysis demonstrated that the V~O2~, V~CO2~, and energy expenditure of HFD-fed Agrp^∆J3^ mice and Pomc^∆J3^ mice were similar to control mice ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Together, these data demonstrate that JNK3 in AgRP neurons, but not POMC neurons, acts to suppress HFD consumption.10.7554/eLife.10031.012Figure 5.JNK3 in AgRP neurons, but not POMC neurons, regulates food consumption.(**A**,**B**) Food consumption by CD-fed and HFD-fed (4 wk) mice was measured (mean ± SEM; n = 8; \*p\<0.05). JNK3 deficiency in POMC neurons was studied by comparing *Pomc-cre* control mice (Pomc^WT^ mice) and *Pomc-cre Mapk10^LoxP/LoxP^*mice (Pomc^∆J3^ mice). JNK3 deficiency in AgRP neurons was studied by comparing *Agrp-cre* control mice (Agrp^WT^ mice) and *Agrp-cre Mapk10^LoxP/LoxP^*mice (Agrp^∆J3^ mice). (**C**,**D**) CD-fed and HFD-fed (16 wk) control mice and mice with JNK3 deficiency in POMC neurons (**C**) and AgRP neurons (**D**) or were tested using glucose tolerance assays and by measurement of fasting blood glucose concentration (mean ± SEM; n = 8\~12; \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001). (**E**,**F**) Representative hematoxylin & eosin-stained sections of liver, epididymal WAT, and interscapular BAT from CD-fed and HFD-fed (16 wk) control mice and mice with JNK3 deficiency in POMC neurons (**E**) and AgRP neurons (**F**) are presented.**DOI:** [http://dx.doi.org/10.7554/eLife.10031.012](10.7554/eLife.10031.012)10.7554/eLife.10031.013Figure 5---figure supplement 1.Effect of JNK3 deficiency in AgRP and POMC neurons on energy expenditure.(**A**) CD-fed and HFD-fed (4 wk) Agrp^WT^ and Agrp^∆J3^ mice mice were examined using metabolic cages to measure V~O2~, V~CO2~, and energy expenditure (mean ± SEM; n=8; p\>0.05). (**B**) CD-fed and HFD-fed (4 wk) Pomc^WT^ and Pomc^∆J3^ mice were examined using metabolic cages to measure V~O2~, V~CO2~, and energy expenditure (mean ± SEM; n=8; \*p\<0.05; \*\*p\<0.01).**DOI:** [http://dx.doi.org/10.7554/eLife.10031.013](10.7554/eLife.10031.013)

JNK3 regulates excitatory transmission onto AgRP neurons of HFD-fed mice {#s2-7}
------------------------------------------------------------------------

Leptin and its receptor are known to affect synaptic transmission and modulate AgRP neuron activity ([@bib42]; [@bib5]). We therefore examined miniature inhibitory postsynaptic currents (mIPSCs) and miniature excitatory postsynaptic currents (mEPSCs) of AgRP neurons in the ARC of WT and *Mapk10^-/-^* mice. This analysis demonstrated that JNK3 deficiency caused no change in mIPSC frequency or amplitude in CD-fed and HFD-fed mice ([Figure 6A--D](#fig6){ref-type="fig"}). Similarly, JNK3 deficiency caused no change in mEPSC frequency or amplitude in CD-fed mice ([Figure 6E--H](#fig6){ref-type="fig"}). In contrast, HFD-fed JNK3-deficient mice demonstrated increased mEPSC amplitudes in the absence of changes in mEPSC frequency ([Figure 6E--H](#fig6){ref-type="fig"}). Studies using the selective antagonist DNQX demonstrated that these mEPSC currents were mediated by AMPA receptors in AgRP neurons ([Figure 6-figure supplement 1](#fig6s1){ref-type="fig"}). Together, these data indicate that JNK3 deficiency leads to altered excitatory transmission onto AgRP neurons compared to WT mice when fed a HFD. This finding is consistent with the increased expression of AgRP and NPY ([Figure 3C](#fig3){ref-type="fig"}) and the increased food consumption ([Figure 1F](#fig1){ref-type="fig"}) observed in HFD-fed JNK3-deficient compared to HFD-fed WT mice.10.7554/eLife.10031.014Figure 6.JNK3 regulates excitatory transmission onto AgRP neurons.(**A**,**B**) *Mapk10^+/+^ Npy-GFP* and *Mapk10^-/-^ Npy-GFP* mice were fed a HFD (3 wk) prior to electrophysiological recording of mIPSC from AgRP neurons. (**C**,**D**) mIPSC frequency (freq.) and amplitude (amp.) in recordings of CD-fed and HFD-fed mice were quantitated (mean ± SEM; n=11\~12; \*p\<0.05). (**E**,**F**) *Mapk10^+/+^ Npy-GFP* and *Mapk10^-/-^ Npy-GFP* mice were fed a HFD (3 wk) prior to electrophysiological recording of mEPSC from AgRP neurons. (**G**,**H**) mEPSC frequency and amplitude in recordings of CD-fed and HFD-fed mice were quantitated (mean ± SEM; n=10; \*p\<0.05).**DOI:** [http://dx.doi.org/10.7554/eLife.10031.014](10.7554/eLife.10031.014)10.7554/eLife.10031.015Figure 6---figure supplement 1.The AMPA receptor antagonist DNQX blocks mEPSCs in AgRP neurons.mEPSCs of arcuate AgRP neurons from *Npy-GFP* mice were recorded under baseline conditions (perfusion with aCSF) and following addition of 10 µM DNQX. The data presented are representative of three recordings from single neurons. The selective AMPA receptor antagonist (DNQX) blocks all mEPSCs recorded at -60 mV. Extracellular Mg2^+^ in the bath solution blocks NMDA receptor-mediated currents at this holding potential.**DOI:** [http://dx.doi.org/10.7554/eLife.10031.015](10.7554/eLife.10031.015)

Discussion {#s3}
==========

The JNK signaling pathway is implicated in the metabolic stress response ([@bib45]). Studies of the ubiquitously expressed isoforms JNK1 and JNK2 demonstrate that the JNK pathway is activated in peripheral tissues by feeding a HFD ([@bib25]). Consequences of HFD-stimulated JNK1 and JNK2 activation in peripheral tissues include promotion of insulin resistance in adipose tissue, liver, and muscle ([@bib44]; [@bib46]; [@bib55]). In contrast, central actions of JNK1 and JNK2 are mediated by the hypothalamic-pituitary axis by regulation of energy expenditure ([@bib6]; [@bib43]; [@bib54]). Together, these studies indicate that JNK1 and JNK2 play important roles in metabolic stress responses by causing insulin resistance in peripheral tissues and promoting obesity by suppressing energy expenditure ([@bib45]).

JNK3 is expressed in a limited number of tissues, including the brain and testis ([@bib24]). Since JNK1 and JNK2 are expressed ubiquitously, the expression of JNK3 by neurons means that these cells express all three JNK isoforms ([@bib16]). To examine the role of JNK in neurons, the effects of ablation of the three genes that encode JNK (*Mapk8, Mapk9*, and *Mapk10*) in neurons have been examined. This analysis demonstrated that compound JNK-deficiency caused markedly increased survival responses associated with increased autophagy ([@bib56]). Roles for individual JNK isoforms in neurons have also been studied ([@bib12]). JNK1 and, to some extent JNK2, are constitutively activated and are primarily localized to axons and dendrites ([@bib11]; [@bib38]) where they play a major role in the regulation of the cytoskeleton and axonal/dendritic morphology ([@bib12]). In contrast, JNK3 exhibits low basal activity and is activated in the nucleus when neurons are exposed to stress ([@bib57]). Studies of *Mapk10^-/-^* mice demonstrate that JNK3 is required for stress-induced cJun phosphorylation and AP-1 activation in neurons ([@bib57]). This role of JNK3 in neurons is non-redundant with JNK1 and JNK2.

Here we report that JNK3 in LEPRb^+^ neurons regulates feeding behavior in mice ([Figure 4](#fig4){ref-type="fig"}). The mechanism of JNK3 function requires metabolic stress (e.g. feeding a HFD) to cause JNK3 activation. This distinguishes the JNK3 deficiency phenotype from other negative regulators of leptin signaling. Thus, JNK3 deficiency does not cause hyperphagia when mice are fed a chow diet, but JNK3 deficiency does cause hyperphagia when mice are fed a HFD. In contrast, PTPN1-deficiency causes hypophagia on both CD and HFD ([@bib7]). This analysis indicates that JNK3 is not required for fine-tuning leptin receptor signaling, but JNK3 is essential for determining the leptin signaling response during exposure to metabolic stress. JNK3 therefore serves a key role in the establishment of the set-point for the threshold of leptin signaling that controls feeding behavior in response to metabolic stress.

Gene ablation studies in sub-populations of LEPRb^+^ neurons demonstrated that HFD (but not CD) hyperphagia was found in mice with JNK3 deficiency in AgRP neurons, but not POMC neurons ([Figure 5](#fig5){ref-type="fig"}). These data demonstrate that JNK3 deficiency in AgRP neurons is sufficient to cause HFD hyperphagia, although possible roles for JNK3 in other LEPRb^+^ neurons cannot be excluded by this analysis. We conclude that orexigenic signaling by AgRP neurons contributes to the effects of JNK3 deficiency on HFD hyperphagia.

Molecular mechanisms that account for JNK3 function include altered excitatory transmission to AgRP neurons in HFD-fed mice. Our recordings measured glutamatergic transmission from all inputs to AgRP neurons and demonstrated an increase in mEPSC amplitude, but not frequency, from HFD-fed JNK3-deficient mice compared with HFD-fed control mice ([Figure 6](#fig6){ref-type="fig"}). This observation is consistent with a possible postsynaptic function of JNK3 in AgRP neurons whereby JNK3 affects AMPA and/or NMDA receptor activity within these neurons. Interestingly, glutamatergic input to AgRP neurons stimulates feeding behavior ([@bib32]). Previous studies have established functional connections between the JNK signaling pathway and glutamatergic receptor signaling in neurons. For example, the JNK scaffold proteins JIP1/2 can regulate NMDA receptor signaling ([@bib28]) and AMPA receptor phosphorylation by JNK regulates AMPA receptor function and trafficking ([@bib49]). Further studies are required to identify the complete spectrum of JNK3 targets in AgRP neurons. Nevertheless, since an increased AMPA response was detected in JNK3-deficient AgRP neurons ([Figure 6H](#fig6){ref-type="fig"} and [Figure 6-figure supplement 1](#fig6s1){ref-type="fig"}), we conclude that JNK-mediated AMPA receptor regulation ([@bib49]) may contribute to the hyperphagic phenotype of HFD-fed JNK3-deficient mice.

The results of the present study indicate that JNK3 plays a major role in the regulation of energy balance. This function of JNK3 to regulate feeding behavior differs from the roles of JNK1/JNK2 to regulate energy expenditure and insulin resistance ([@bib45]). These conclusions are based on loss-of-function studies. A contrasting conclusion has been reported based on gain-of-function studies using transgenic expression of a MKK7-JNK1 fusion protein (that mimics constitutively activated JNK1) in AgRP neurons that causes a small increase in food consumption by CD-fed mice ([@bib51]). Since JNK1-deficient (*Mapk8^-/-^*) mice do not exhibit altered feeding behavior ([@bib44]) and endogenous JNK1 is constitutively activated in neurons ([@bib12]), it is unclear why transgenic over-expression of an activated *Mapk8* allele (encoding a MKK7-JNK1 fusion protein) in WT mice would cause a small change in feeding behavior. However, the pro-apoptotic function of this activated *Mapk8* allele ([@bib31]) may cause defects in hypothalamic neuronal circuits that contribute to the reported phenotype. On balance, we favor the conclusion that JNK1 and JNK2 do not influence feeding behavior ([@bib45]), but JNK3 promotes leptin-mediated suppression of HFD feeding behavior (when JNK3 is activated), but not CD feeding behavior (when JNK3 is inactive).

The observation that JNK1 and JNK2 promote obesity (by inhibiting energy expenditure) and cause insulin resistance in peripheral tissues indicates that drugs that block JNK signaling may be therapeutically beneficial for the treatment of pre-diabetes ([@bib45]). However, this study demonstrates that JNK3 inhibition causes HFD-dependent hyperphagia ([Figure 1F](#fig1){ref-type="fig"}). This represents a potential problem for drug therapy. While JNK1/2 inhibition may be therapeutically beneficial, hyperphagia may therefore result from JNK3 inhibition. Consequently, the most effective drug strategy for the treatment of pre-diabetes may require a small molecule that inhibits JNK1/2, but not JNK3.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

We have described *Mapk10^-/-^* mice previously ([@bib57]). We obtained C57BL/6J mice (stock number 000664), B6.129S4-*Gt(ROSA)26Sor^tm1(FLP1)Dym^*/RainJ ([@bib20]) (stock number 009086), B6.129-*Lepr^tm2(cre)Rck^*/J mice ([@bib18]) (stock number 008320), B6.FVB-Tg(Npy-hrGFP)1Lowl/J mice ([@bib52]) (stock number 006417), *Agrp^tm1(cre)Lowl^*/J mice ([@bib50]) (stock number 012899), and Tg(Pomc1-cre)16Lowl/J mice ([@bib3]) (stock number 005965) from the Jackson Laboratory. These mice were backcrossed to the C57BL/6J genetic background.

We established *Mapk10^LoxP/LoxP^* mice using homologous recombination in C57BL/6N embryonic stem cells, the generation of chimeric mice, and breeding to obtain germ-line transmission of the floxed *Mapk10* allele using standard procedures. The mice used for these studies were backcrossed to the C57BL/6J strain. The *Frt-Neo* cassette was excised by crossing the mice with FLP transgenic mice. Homologous recombination of 5' arm of the targeting vector was verified by PCR using the primers 1F: 5'-TGTGACCTTCTAATACAG-3' and 2R: 5'-CCTAAGACTGTCAGAGAG-3' (*Mapk10^+^*: 135 bp; *Mapk10^LoxP^*: 282 bp). Homologous recombination of the 3' arm of the targeting vector was verified by PCR using the primers (3F: 5'-CTGAGTGACGTGTGGAG-3' and 5R: 5'-TCATTGGGTTGGGATATTC-3') followed by digestion with *XhoI (Mapk10^+^*: 1,975 bp; *Mapk10^LoxP^*: 1026 bp & 1028 bp). *Cre*-mediated recombination between the *LoxP* sites was detected by PCR using the primers 1F and 4R: 5'-GATTCTCCCTGTCTGAG-3' (*Mapk10^+^*: 1008 bp; *Mapk10^Loxp^*: 1759 bp; *Mapk10^∆^*: 171 bp). The *Mapk10*^LoxP/LoxP^ mice were routinely genotyped by PCR using primers 1F and 2R (*Mapk10^+^*: 135 bp; *Mapk10^LoxP^*: 282 bp).

Male mice (8 wks old) were fed a chow diet (Iso Pro 3000, Purina) or a HFD (F3282, Bioserve) for 4 to 12 wks. Body weight was measured on a weekly basis and whole body fat and lean mass were non-invasively measured using ^1^H-MRS (Echo Medical Systems, Houston, TX). The mice were housed in a facility accredited by the American Association for Laboratory Animal Care (AALAC). The Institutional Animal Care and Use Committee (IACUC) of the University of Massachusetts and the University of Cincinnati approved all studies using animals.

Hyperinsulinemic-euglycemic clamp studies {#s4-2}
-----------------------------------------

The clamp studies were performed at the National Mouse Metabolic Phenotyping Center at the University of Massachusetts Medical School. A 2 hr hyperinsulinemic-euglycemic clamp was conducted using overnight fasted conscious mice with a primed and continuous infusion of human insulin (150 mU/kg body weight priming followed by 2.5 mU/kg/min; Humulin; Eli Lilly), and 20% glucose was infused at variable rates to maintain euglycemia ([@bib29]).

Metabolic cages {#s4-3}
---------------

The analysis was performed by the National Mouse Metabolic Phenotyping Centers at the University of Massachusetts Medical School and the University of Cincinnati. The mice were housed under controlled temperature and lighting with free access to food and water. The food/water intake, energy expenditure, respiratory exchange ratio, and physical activity were measured using metabolic cages (TSE Systems, Chesterfield, MO).

Leptin treatment {#s4-4}
----------------

Intracerebroventricular treatment with leptin was performed using mice with a cannula stereotaxically implanted into the 3^rd^ ventricle (coordinates from Bregma: anteroventral, -1.8 mm; lateral, 0.0 mm; dorsoventral, 5.0 mm). Mice were monitored daily and allowed to recover for 1 week after surgery. Mice received either solvent (artificial cerebrospinal fluid; aCSF) or Leptin (5 µg) in 2 µl delivered over 10 min. Leptin treatment by intraperitoneal (ip) injection was performed following 3 consecutive days of sham injection.

RNA analysis {#s4-5}
------------

Tissue isolated from mice starved overnight was used to isolate total RNA using the RNAeasy mini kit (Qiagen). Total RNA (500 ng) was converted into cDNA using the high capacity cDNA reverse transcription kit (Life Technologies, Carlsbad, CA). The diluted cDNA was used for real-time quantitative PCR analysis using a Quantstudio PCR PCR machine (Life Technologies). TaqMan assays (Life Technologies) were used to quantify *Adipoq* (Mm00456425_m1), *Agrp* (Mm00475829_g1), *Arg1* (Mm00475988_m1), *Ccl2* (Mm00441242_m1), *Emr1* (F4/80) (Mm00802530_m1), *Il1b* (Mm00434228_m1), *Il6* (Mm00446190_m1), *Mapk8 (Jnk1)* (Mm00489514_m1), *Mapk9 (Jnk2)* (Mm00444231_m1), *Mapk10 (Jnk3)* (Mm00436518_m1), *Mgl2* (Mm00460844_m1), *Mrc1* (Mm00485148_m1), *Mrc2* (Mm00485184_m1), *Npy* (Mm03048253_m1), *Pomc* (Mm00435874_m1), and *Tnf* (Mm00443258_m1). The relative mRNA expression was normalized by measurement of the amount of *18S* RNA in each sample using Taqman^©^ assays (catalog number 4308329; Life Technologies).

Blood analysis {#s4-6}
--------------

Blood glucose was measured with an Ascensia Breeze 2 glucometer (Bayer, Pittsburgh, PA). Adipokines and insulin in plasma were measured by multiplexed ELISA using a Luminex 200 machine (Millipore, Billerica, MA).

Glucose and insulin tolerance tests {#s4-7}
-----------------------------------

Glucose and insulin tolerance tests were performed by intraperitoneal injection of mice with glucose (1 g/kg) or insulin (1.5 U/kg) using methods described previously ([@bib44]).

JNK3 activation {#s4-8}
---------------

Mice (8--12 week-old) were fasted overnight. Hypothalamic extracts were prepared using Triton lysis buffer (20 mM Tris-pH 7.4, 1% Triton-X100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM β-glycerophosphate, 1 µM sodium orthovanadate, 1 µM PMSF and 10 µg/mL leupeptin and aprotinin). Extracts (30--50 µg of protein) were examined by immunoblot analysis by probing with antibodies to JNK3 (Cell Signaling Technologies, Danvers, MA) and GAPDH (Santa Cruz Biotechnology, Dallas, TX). Activated JNK was isolated by immunoprecipitation with the mouse monoclonal p-JNK antibody G9 (Cell Signaling Technologies) pre-bound to protein G Sepharose (GE Healthcare, Pittsburgh, PA) and detected by immunoblot analysis by probing with an antibody to JNK3 (Cell Signaling Technologies). Immunocomplexes were detected by fluorescence using anti-mouse and anti-rabbit secondary IRDye antibodies (LI-COR Biosciences, Lincoln, NE) and quantitated using the Li-COR Imaging system

Analysis of tissue sections {#s4-9}
---------------------------

Histology was performed using tissue fixed in 10% formalin for 24 h, dehydrated, and embedded in paraffin. Sections (7 µm) were cut and stained using hematoxylin & eosin (American Master Tech Scientific, Lodi, CA). Paraffin sections were stained with an antibody to F4/80 (Abcam, Cambridge, MA) that was detected by incubation with anti-rabbit Ig conjugated to Alexa Fluor 488 (Life Technologies). DNA was detected by staining with DAPI (Life Technologies). Fluorescence was visualized using a Leica TCS SP2 confocal microscope equipped with a 405 nm diode laser (Leica Microsystems, Buffalo Grove, IL).

Electrophysiology {#s4-10}
-----------------

Brain slice preparations were performed using 8--10-weeks-old mice anaesthetized with isoflurane before decapitation and removal of the entire brain. The brains were immediately submerged in ice-cold, carbogen-saturated (95% O~2~, 5% CO~2~) high sucrose solution (238 mM sucrose, 26 mM NaHCO~3~, 2.5 mM KCl, 1.0 mM NaH~2~PO~4~, 5.0 mM MgCl~2~, 10.0 mM CaCl~2~, 11 mM glucose). Then, 300 µm thick coronal sections were cut with a Leica VT1000S Vibratome and incubated in oxygenated aCSF (126 NaCl, 21.4 mM NaHCO~3~, 2.5 mM KCl, 1.2 mM NaH~2~PO~4~, 1.2 mM MgCl~2~, 2.4 mM CaCl~2~, 10 mM glucose) at 34°C for 30 min. The slices were maintained and recorded at room temperature (20--24°C). The intracellular solution for voltage clamp recording contained the following: 140 mM CsCl, 1 mM BAPTA, 10 mM HEPES, 5 mM MgCl~2~, 5 mM Mg-ATP, and 0.3 mM Na~2~GTP, pH 7.35 and 290 mOsm.

To isolate glutamatergic, action potential-independent events, minitature excitatory postsynaptic currents (mEPSCs) were recorded in the presence of tetrodotoxin (1 µM) and picrotoxin (100 μM) in whole cell voltage clamp mode. To record miniature inhibitory postsynaptic currents (mIPSCs), the neurons were recorded in the presence of TTX and kynurenic acid (1 mM). The membrane potential was clamped at −60 mV. All recordings were made using a Multiclamp 700B amplifier, and data were filtered at 1.4 kHz and digitized at 20 kHz. Data was analyzed using Clampfit 10.2 and Origin Pro 8.6.

Statistical analysis {#s4-11}
--------------------

Differences between groups were examined for statistical significance using the Student's test or analysis of variance (ANOVA) with the Fisher's test.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"JNK3 participates in an AgRP/NPY neuron circuit that suppresses feeding behavior in response to metabolic stress\" for peer review at *eLife*. Your submission has been favorably evaluated by Tony Hunter (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

All the reviewers agree that this manuscript does a fine job of demonstrating that JNK3 function is important for body weight regulation and that its function in AgRP-expressing neurons is particularly important. However, the mechanism(s) by which JNK3 acts within AgRP neurons is not sufficiently developed. In particular the deficiency in Lepr signaling seems unlikely.

Essential revisions:

For publication in *eLife*, the authors need to delineate the mechanism by which loss of JNK3 signaling in AgRP neurons promotes obesity. The reviewers have suggested several approaches to address this issue. Alternatively, the authors may decide that publishing the more descriptive part of the study ([Figures 1](#fig1){ref-type="fig"}--[5](#fig5){ref-type="fig"}) in another journal is the best option.

*Reviewer \#1:*

This paper provides evidence that lack of JNK3 expression in all cells, all neurons that express the leptin-receptor or just the sub-population of neurons that expresses AgRP leads to obesity when mice are reared on a high-fat diet (HFD) but not on a normal (control diet). The obesity is associated with elevated leptin, elevated insulin, glucose intolerance, insulin resistance, and many other parameters associated with obesity. The most important contribution is their systematic demonstration that the phenotype of global KO of the gene encoding JNK3 is replicated quite well by KO only in AgRP neurons. The authors go on to explore how loss of JNK3 function in AgRP neurons might lead to the hyperphagic obese phenotype, but those studies are less compelling.

1\) The authors show that leptin receptors can be activated (phosphorylated) in the JNK3 KO but the dose-response is apparently shifted -- LepR is fully activated (phosphorylated) with 2.5 mg/kg leptin but only partially activated with 0.1 mg/kg (Figure 7B). They attribute this hypo-sensitivity to a reduced level of Lepr mRNA (about half normal). They show that phospho-cJun (transcription factor) normally binds to an AP1 site in the promoter of Lepr gene and hence the lack of phosphorylation of c-Jun could impair transcription of Lepr gene. There are two problems with this analysis: (a) The Lepr mRNA (rather than protein) measurements were made in hypothalamic samples, not in AgRP neurons where it is relevant. (b) Complete loss of Lepr in AgRP neurons has a relatively small effect on obesity and heterozygous Lepr db/+ mice (with half the normal level of Lepr mRNA) do not become more obese on a HFD than WT mice. Thus, it seems unlikely that reduced levels of LepR account for the obesity observed in this JNK3 KO model.

2\) Their data in [Figure 6](#fig6){ref-type="fig"} are more promising. They show that mEPSCs amplitude in AgRP neurons is enhanced in slices, suggestive of enhanced excitatory signaling within AgRP neurons. If this enhanced excitability extends to in vivo situation, then that could drive the hyperphagia and ultimately the obesity. Thus, I suggest that the authors do whatever they can to demonstrate that AgRP neurons are hyperactive in vivo. First they need to demonstrate that the mice are hyperphagic *before* they become obese. The experiment in [Figure 4C](#fig4){ref-type="fig"} was performed after there was already a difference in body weight. A pair-feeding experiment would also be useful to demonstrate that the obesity is due to hyperphagia. Looking for markers of enhanced neuronal activity in AgRP neurons (e.g. Fos) might also be revealing. However, the ultimate experiment would be to use in vivo recording or calcium imaging of AgRP neurons -- techniques that are available to this group.

*Reviewer \#2:*

Vernia and colleagues present an interesting paper in which the conclusion are based on a broad set of experiments and well justified. They show that the loss of the neuronally expressed JNK3 is associated with increased obesity due to increased food consumption. This is brought about by the elimination of JNK3 in leptin receptor expressing neurons. They narrow this down further by doing an AgRP-specific elimination and compare that to a POMC neuronal-specific elimination. They demonstrate hyperphagia to be present in only Agrp-specific nulls for JNK3. They go on to demonstrate that this is in fact due at least in part due to reduced leptin receptor expression on AgRP-neurons. All of this happens exclusively in the context of high fat diet exposure.

These are interesting findings that should be of broad interest to the field. It is surprising to find JNK3 necessary for leptin receptor expression and to see it distinct from the role of JNK1/2 in the periphery where their lack results in improvement in the metabolic phenotype due to reduced inflammatory tone.

There is very little to criticize here. The authors address an important question, find a surprising answer of broad interest and base their conclusion on a broad set of genetic data.

The only area that falls short is a further analysis of the signaling mechanisms in place. What other component of leptin signaling are affected by the lack of JNK3? The downstream analysis could be broader. Where does the cell specificity come in? How does JNK3 deficiency lead to reduce *lepR* expression in AgRP neurons, and it does not lead to reduced *lepR* expression in POMC neurons?

*Reviewer \#3:*

In this manuscript Vernia et al. show that JNK3 plays a role in inhibiting high-fat diet-induced weight gain and does so through actions at AgRP/NPY neurons, which may include bolstering leptin actions. Overall, the metabolic studies convincingly show that JNK3 deficiency increases HFD-induced weight gain, hyperphagia, adipose hypertrophy, glucose intolerance and insulin resistance. The logical set of cell-type-selective JNK3 deletions provides compelling evidence that JNK3 actions specifically in AgRP neurons are necessary to reduce HFD-induced weight gain. Thus, the overall conclusion is well supported by the data presented in [Figures 1](#fig1){ref-type="fig"}--[5](#fig5){ref-type="fig"}.

The primary weakness in the work is the cursory attempt to provide some mechanistic insight (Figures 6 and 7). The mEPSC recordings add very little to the paper as is. It is important to know that mIPSCs don\'t also increase and how the deletion affects basal regulation of POMC neurons. In Figure 7, the overall JNK3 knockout was used and thus, it is not possible to determine if leptin receptor expression is also reduced in POMC cells or rather, if maybe POMC cells do not express JNK3 or require JNK3 to bolster leptin sensitivity. In my opinion, these last 2 experiments do not need to be included to support the conclusions made, but if they are included, they need to be done more thoroughly so that they can be better interpreted.

JNK3 is the neuron-specific isoform of JNK and its activity is dynamically regulated rather than constitutive like the other 2 isoforms. Together with the compelling evidence provided here that JNK3 helps reduce high-fat diet-induced weight gain through actions in AgRP neurons, this work adds significant new insight into JNK3 function and the hypothalamic regulation of energy balance in the face of metabolic challenge.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for submitting your work entitled \"Excitatory transmission onto AgRP neurons is regulated by cJun NH~2~-terminal kinase 3 in response to metabolic stress\" for consideration by *eLife*. Your article has been evaluated by a Reviewing Editor and overseen by Tony Hunter as the Senior Editor.

In response to our reviews, the authors of this paper have now dropped data (old Figure 7) suggesting that reduced leptin receptor expression was responsible for the obesity of JNK3-deficient mice in favor enhanced glutamatergic (mEPSC) signaling ([Figure 6](#fig6){ref-type="fig"}). The authors have added panels to [Figure 6](#fig6){ref-type="fig"} showing that inhibitory (mIPSC) is unchanged. Overall, the hypothesis that enhanced glutamatergic signaling (excitation) of AgRP neurons would maintain *Npy* and *Agrp* expression and enhance feeding behavior makes sense, especially because the previous work from the Lowell lab (Liu et al., 2012) showing that removing NMDA receptors from AgRP neurons has the opposite effect. However, there are a few loose ends that need attention.

1\) Unfortunately, the electrophysiology experiments were performed on *Mapk10* KO mice rather than mice lacking *Mapk10* selectively in AgRP neurons; hence, it is not possible to make a strong conclusion that the enhanced excitatory transmission is due to lack of JNK3 in AgRP neurons.

2\) The authors suggest in the Discussion that NMDA signaling is enhanced, but their experiments do not distinguish NMDA from AMPA signaling.

3\) The hypothesis that links JNK3 deficiency and the presumptive enhanced NMDA signaling is not clearly explained. In the fifth paragraph of the Discussion the authors say that JIP proteins might be involved and refer to Kennedy et al. (2007). If I understand that paper correctly, it suggests that lack of JIP proteins influences JNK localization (activity) and prevents phosphorylation of NR2 subunit of NMDA receptor. If so, it seems like lack of JNK3 would impair (not enhance) NMDA function in the present studies. The authors admit that \"further studies are required to identify the complete spectrum of JNK3 targets in AgRP neurons\". I would argue that they have not identified any direct JNK3 targets in AgRP neurons.

Essential revisions:

At the very least, the authors need to discern whether AMPA or NMDA receptor signaling is altered in JNK3-deficient AgRP neurons and provide some data or reasonable hypothesis indicating how lack of JNK3 could lead to enhanced AMPA/NMDA signaling.

10.7554/eLife.10031.017

Author response

*Essential revisions:*

*For publication in eLife, the authors need to delineate the mechanism by which loss of JNK3 signaling in AgRP neurons promotes obesity. The reviewers have suggested several approaches to address this issue. Alternatively, the authors may decide that publishing the more descriptive part of the study ([Figures 1](#fig1){ref-type="fig"}--[5](#fig5){ref-type="fig"}) in another journal is the best option.*

Thank you for providing this opportunity to improve our manuscript. We have carefully considered the reviewers' comments and we have thoroughly revised the manuscript by including new experiments to more fully establish our conclusions. Specifically, we demonstrate that JNK3 plays no role in the regulation of feeding behavior in chow-fed mice, but activated JNK3 in high fat diet-fed mice regulates excitatory transmission onto ARP/NPY neurons. Collectively, our data establish a new paradigm for the regulation of feeding behavior by metabolic stress.

*Reviewer \#1: This paper provides evidence that lack of JNK3 expression in all cells, all neurons that express the leptin-receptor or just the sub-population of neurons that expresses AgRP leads to obesity when mice are reared on a high-fat diet (HFD) but not on a normal (control diet). The obesity is associated with elevated leptin, elevated insulin, glucose intolerance, insulin resistance, and many other parameters associated with obesity. The most important contribution is their systematic demonstration that the phenotype of global KO of the gene encoding JNK3 is replicated quite well by KO only in AgRP neurons. The authors go on to explore how loss of JNK3 function in AgRP neurons might lead to the hyperphagic obese phenotype, but those studies are less compelling. 1) The authors show that leptin receptors can be activated (phosphorylated) in the JNK3 KO but the dose-response is apparently shifted -- LepR is fully activated (phosphorylated) with 2.5 mg/kg leptin but only partially activated with 0.1 mg/kg (Figure 7B). They attribute this hypo-sensitivity to a reduced level of Lepr mRNA (about half normal). They show that phospho-cJun (transcription factor) normally binds to an AP1 site in the promoter of Lepr gene and hence the lack of phosphorylation of c-Jun could impair transcription of Lepr gene. There are two problems with this analysis: (a) The Lepr mRNA (rather than protein) measurements were made in hypothalamic samples, not in AgRP neurons where it is relevant. (b) Complete loss of Lepr in AgRP neurons has a relatively small effect on obesity and heterozygous Lepr db/+ mice (with half the normal level of Lepr mRNA) do not become more obese on a HFD than WT mice. Thus, it seems unlikely that reduced levels of LepR account for the obesity observed in this JNK3 KO model.*

We agree. These data have been removed from the revised manuscript. Conclusions about leptin receptor expression have also been removed from the text. The mechanistic analysis in the revised manuscript focuses on the role of JNK3 to regulate excitatory transmission onto ARP/NPY neurons.

*2) Their data in [Figure 6](#fig6){ref-type="fig"} are more promising. They show that mEPSCs amplitude in AgRP neurons is enhanced in slices, suggestive of enhanced excitatory signaling within AgRP neurons. If this enhanced excitability extends to in vivo situation, then that could drive the hyperphagia and ultimately the obesity. Thus, I suggest that the authors do whatever they can to demonstrate that AgRP neurons are hyperactive in vivo. First they need to demonstrate that the mice are hyperphagic before they become obese. The experiment in [Figure 4C](#fig4){ref-type="fig"} was performed after there was already a difference in body weight. A pair-feeding experiment would also be useful to demonstrate that the obesity is due to hyperphagia. Looking for markers of enhanced neuronal activity in AgRP neurons (e.g. Fos) might also be revealing. However, the ultimate experiment would be to use in vivo recording or calcium imaging of AgRP neurons -- techniques that are available to this group.*

We have revised the manuscript to address these important points:

A\) We performed a time course analysis using metabolic cages to examine when hyperphagia is detected in mice fed a high fat diet. This analysis demonstrates that hyperphagia is detected within 2 days of high fat diet consumption ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). ^1^H-MRS analysis on day 3 demonstrated no obesity phenotype ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). These data demonstrate that the high fat diet hyperphagia phenotype occurs prior to the development of obesity.

B\) We performed a pair-feeding study using high fat diet-fed WT and JNK3-deficient mice. This analysis demonstrates that no obesity phenotype was detected when the WT and JNK3-deficient mice consumed the same amount of food ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). These data demonstrate that the greater obesity of high fat diet-fed JNK3-deficient mice compared with WT mice is caused by increased food consumption.

C\) We have not performed in vivo recording and calcium imaging of AgRP neurons, as requested; we believe that such studies are beyond the scope of the present manuscript. We did examine cFos staining, but no differences in the number of cFos-positive AgRP neurons were detected between WT and JNK3 KO mice. We have expanded the electrophysiological analysis of AgRP neurons from chow diet-fed mice and high fat diet-fed mice in the revised manuscript ([Figure 6](#fig6){ref-type="fig"}). This analysis demonstrates that JNK3-deficiency causes no phenotype in chow diet-fed mice, but does cause increased mEPSC amplitude in high fat diet-fed mice ([Figure 6](#fig6){ref-type="fig"}).

*Reviewer \#2: \[...\] There is very little to criticize here. The authors address an important question, find a surprising answer of broad interest and base their conclusion on a broad set of genetic data. The only area that falls short is a further analysis of the signaling mechanisms in place. What other component of leptin signaling are affected by the lack of JNK3? The downstream analysis could be broader. Where does the cell specificity come in? How does JNK3 deficiency lead to reduce lepR expression in AgRP neurons, and it does not lead to reduced lepR expression in POMC neurons?*

Based on the comments of the other reviewers, we have deleted the section of the original manuscript on LepRb expression. In the revised manuscript, we have focused the data presentation and the central conclusions of our study on the finding that excitatory transmission onto AgRP neurons is regulated by the JNK3 signaling pathway in HFD-fed mice. This observation provides a mechanism for the HFD-specific hyperphagia of JNK3 KO mice. Further studies will be required to identify direct molecular targets of JNK3 signaling; this analysis is beyond the scope of the present study.

*Reviewer \#3: \[...\] The primary weakness in the work is the cursory attempt to provide some mechanistic insight (Figures 6 and 7). The mEPSC recordings add very little to the paper as is. It is important to know that mIPSCs don\'t also increase and how the deletion affects basal regulation of POMC neurons. In Figure 7, the overall JNK3 knockout was used and thus, it is not possible to determine if leptin receptor expression is also reduced in POMC cells or rather, if maybe POMC cells do not express JNK3 or require JNK3 to bolster leptin sensitivity. In my opinion, these last 2 experiments do not need to be included to support the conclusions made, but if they are included, they need to be done more thoroughly so that they can be better interpreted.*

We agree that the leptin receptor expression data do not strengthen our study. Based on this criticism and the comments of reviewer \#1, we have deleted these data from the revised manuscript. We have revised the manuscript to include new data to document mIPSCs ([Figure 6](#fig6){ref-type="fig"}) and we have more fully documented the changes in mEPSCs. We believe that these data do strengthen the study.

JNK3 is the neuron-specific isoform of JNK and its activity is dynamically regulated rather than constitutive like the other 2 isoforms. Together with the compelling evidence provided here that JNK3 helps reduce high-fat diet-induced weight gain through actions in AgRP neurons, this work adds significant new insight into JNK3 function and the hypothalamic regulation of energy balance in the face of metabolic challenge.

Thank you for these comments.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*In response to our reviews, the authors of this paper have now dropped data (old Figure 7) suggesting that reduced leptin receptor expression was responsible for the obesity of JNK3-deficient mice in favor enhanced glutamatergic (mEPSC) signaling ([Figure 6](#fig6){ref-type="fig"}). The authors have added panels to [Figure 6](#fig6){ref-type="fig"} showing that inhibitory (mIPSC) is unchanged. Overall, the hypothesis that enhanced glutamatergic signaling (excitation) of AgRP neurons would maintain Npy and Agrp expression and enhance feeding behavior makes sense, especially because the previous work from the Lowell lab (Liu et al., 2012) showing that removing NMDA receptors from AgRP neurons has the opposite effect. However, there are a few loose ends that need attention.*

*1) Unfortunately, the electrophysiology experiments were performed on Mapk10 KO mice rather than mice lacking Mapk10 selectively in AgRP neurons; hence, it is not possible to make a strong conclusion that the enhanced excitatory transmission is due to lack of JNK3 in AgRP neurons.*

*2) The authors suggest in the Discussion that NMDA signaling is enhanced, but their experiments do not distinguish NMDA from AMPA signaling.*

*3) The hypothesis that links JNK3 deficiency and the presumptive enhanced NMDA signaling is not clearly explained. In the fifth paragraph of the Discussion the authors say that JIP proteins might be involved and refer to Kennedy et al. (2007). If I understand that paper correctly, it suggests that lack of JIP proteins influences JNK localization (activity) and prevents phosphorylation of NR2 subunit of NMDA receptor. If so, it seems like lack of JNK3 would impair (not enhance) NMDA function in the present studies. The authors admit that \"further studies are required to identify the complete spectrum of JNK3 targets in AgRP neurons\". I would argue that they have not identified any direct JNK3 targets in AgRP neurons.*

Our focus on JNK3 function in AgRP neurons is based on the findings that:

1\) JNK3-deficiency causes changes in *Agrp* and *Npy* expression, but not *Pomc* expression, in the response to leptin administration ([Figure 3B](#fig3){ref-type="fig"}) or feeding a HFD ([Figure 3C](#fig3){ref-type="fig"});

2\) mEPSC amplitudes are increased in AgRP neurons of JNK3-deficient mice ([Figure 6](#fig6){ref-type="fig"}); and

3\) JNK3-deficiency in AgRP neurons is sufficient to cause hyperphagy on a HFD ([Figure 5](#fig5){ref-type="fig"}).

Together, these data provide strong evidence for a function of JNK3 in AgRP neurons. We agree that electrophysiological studies of *AgRP-cre^+^ Mapk10^LoxP/LoxP^ NPY-GFP* mice would be interesting, but these mice are not available in our colony; we consider these studies to be beyond the scope of the present study.

We apologize for the poor presentation of the conclusions of our study in the Discussion section of our manuscript where we suggested that NMDA receptors may be regulated (based on the two papers we cited) without adequately addressing the role of AMPA receptors. We have revised the manuscript to make our presentation clearer. Moreover, we have included new data in the manuscript ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) that demonstrates the role of AMPA responses in the mEPSC recordings. These new data have enabled greater focus of the manuscript. *These data represent a key finding that provides a mechanism for JNK3 function mediated by the regulation of AMPA responses*. It is established that AMPA receptor phosphorylation by JNK controls AMPA receptor trafficking and function (Thomas et al. 2008).

Although an altered AMPA response in AgRP neurons contributes to the JNK3 phenotype, we cannot exclude the possibility that there is also an altered NMDA response. We feel that dissecting the specific contributions of AMPA and NMDA receptors, while interesting, is outside the scope of this study. In addition, while our recordings show alterations in mEPSC amplitudes, further studies are needed to identify the full spectrum of JNK3 targets that could potentially result in this observation. Such targets may include the JNK scaffold protein JIP1 (that inhibits NMDAR signaling) and JIP2 (that increases NMDAR signaling), but we consider studies of these scaffold proteins to be beyond the scope of the present manuscript.

Essential revisions:

*At the very least, the authors need to discern whether AMPA or NMDA receptor signaling is altered in JNK3-deficient AgRP neurons and provide some data or reasonable hypothesis indicating how lack of JNK3 could lead to enhanced AMPA/NMDA signaling.*

We agree -- this is an important point. We did not make conclusions about AMPA vs. NMDA currents in the previous version of this manuscript. We have therefore revised the manuscript to include new data documenting that the mEPSC currents that we detect are mediated by AMPA receptor responses, not NMDA receptor responses ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). These data have enabled us to focus on AMPA responses and the established role of JNK phosphorylation to regulate AMPA receptor trafficking and function (subsection "JNK3 regulates excitatory transmission onto AgRP neurons of HFD-fed mice"). We believe that our revised manuscript has been substantially improved by incorporation of these changes.

[^1]: Genes and Metabolism Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, United Kingdom.

[^2]: These authors contributed equally to this work.
